Washington, D.C. 20549






Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 16, 2020


Vaxart, Inc.

(Exact name of registrant as specified in its charter)












(State or other jurisdiction of incorporation)


(Commission File Number)


(IRS Employer Identification No.)



385 Oyster Point Boulevard, Suite 9A, South San Francisco, California



(Address of principal executive offices)


(Zip Code)


Registrant’s telephone number, including area code: (650) 550-3500


Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 


Securities registered pursuant to Section 12(b) of the Act:


Title of each class


Trading symbol


Name of each exchange on which registered

Common stock, $0.0001 par value




The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


 Emerging Growth Company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐








Item 1.01 Entry into a Material Definitive Agreement.


On November 16, 2020, Vaxart, Inc. (the Company) and Vera Therapeutics, Inc. (“Vera”) entered into a sublease (the “Sublease”) of approximately 24,606 rentable square feet of office and research laboratory space located on the third (3rd) floor of a building located at 170 Harbor Way, South San Francisco, California for a term commencing on December 1, 2020 and terminating on September 30, 2025. The space is currently leased by Vera and the master landlord is Britannia Pointe Grand Limited Partnership. The rent payable under the Sublease is $95,963.40 per month, which amount shall increase by three and one-half percent (3.5%) annually. The Sublease provides for a pass-through of building real estate taxes and expenses.


A copy of the Sublease will be filed as an exhibit to the Company’s next periodic report, and the description of the Sublease is qualified in its entirety by reference to such exhibit.

















Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.






Vaxart, Inc. 














Dated: November 19, 2020










/s/ Andrei Floroiu






Andrei Floroiu






President and Chief Executive Officer